Skip to Content

Bio-Rad Laboratories Inc BIO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Narrow-Moat Bio-Rad Reports Solid Q3 Buoyed by Royalties, COVID-19, and Currency Effects

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Bio-Rad saw a strong quarter across the board in the third quarter, with currency neutral sales growth of 13.8% and EPS growth of 24%, excluding income and taxes from Sartorius. We are maintaining our $455 fair value estimate and our narrow moat and high uncertainty ratings. We continue to believe the market is overestimating Bio-Rad’s postpandemic growth prospects.

Read Full Analysis

Company Profile

Business Description

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Contact
1000 Alfred Nobel Drive
Hercules, CA, 94547
T +1 510 724-7000
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type Classic Growth
Employees 8,000